Adiponectin and its receptor signaling: An anti-cancer therapeutic target and its implications for anti-tumor immunity

Expert Opinion on Therapeutic Targets

Volumn 19, Issue 8, 2015, Pages 1105-1125

  Katira, Arnav ^a   Tan, Peng H ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Adiponectin; adipoR1 R2; anti tumor immunity; cancer; signaling pathway; therapeutic targets

Indexed keywords

ADIPONECTIN; ADIPONECTIN RECEPTOR;

APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER RISK; CANCER THERAPY; CARCINOGENESIS; CELL PROLIFERATION; COLORECTAL CANCER; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; GENETIC POLYMORPHISM; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; KIDNEY CANCER; LIVER CANCER; NONHUMAN; OBESITY; PANCREAS CANCER; PROSTATE CANCER; RENAL CELL CANCER; REVIEW; TUMOR IMMUNITY; ADIPOCYTE; ANIMAL; IMMUNOLOGY; METABOLISM; NEOPLASMS; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ADIPOCYTES; ADIPONECTIN; ANIMALS; APOPTOSIS; CELL PROLIFERATION; HUMANS; NEOPLASMS; RECEPTORS, ADIPONECTIN; SIGNAL TRANSDUCTION;

EID: 84937158849     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2015.1035710     Document Type: Review

References (165)

1. Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003;423(6941):762-9
2. Takemura Y, Ouchi N, Shibata R, et al. Adiponectin modulates inflammatory reactions via calreticulin receptordependent clearance of early apoptotic bodies. J Clin Invest 2007;117(2):375-86
3. van Stijn CM, Kim J, Barish GD, et al. Adiponectin expression protects against angiotensin II-mediated inflammation and accelerated atherosclerosis. PLoS One 2014;9(1):e86404
4. Kissebah AH, Sonnenberg GE, Myklebust J, et al. Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc Natl Acad Sci USA 2000;97(26):14478-83
5. Wang Y, Lam KS, Yau MH, Xu A. Post-translational modifications of adiponectin: mechanisms and functional implications. Biochem J 2008;409(3):623-33
6. Suzuki S, Wilson-Kubalek EM, Wert D, et al. The oligomeric structure of high molecular weight adiponectin. FEBS Lett 2007;581(5):809-14
7. Ujiie H, Oritani K, Kato H, et al. Identification of amino-terminal region of adiponectin as a physiologically functional domain. J Cell Biochem 2006;98(1):194-207
8. Arikoglu H, Ozdemir H, Kaya DE, et al. The adiponectin variants contribute to the genetic background of type 2 diabetes in Turkish population. Gene 2013;pii: S0378-1119(13):01448-0
9. Silva FM, de Almeida JC, Feoli AM. Effect of diet on adiponectin levels in blood. Nutr Rev 2011;69(10):599-612
10. Blanco-Colio LM, Martn-Ventura JL, Gómez-Guerrero C, et al. Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk. Eur J Pharmacol 2008;586(1-3):259-65
11. Lee YJ, Cho S, Kim SR. The association between serum adiponectin levels and nutritional status of hemodialysis patients. Ren Fail 2011;33(5):506-11
12. Zappala G, Rechler MM. IGFBP-3, hypoxia and TNF-alpha inhibit adiponectin transcription. Biochem Biophys Res Commun 2009;382(4):785-9
13. Saunders TJ, Palombella A, McGuire KA, et al. Acute exercise increases adiponectin levels in abdominally obese men. J Nutr Metab 2012;2012:148729
14. Isobe T, Saitoh S, Takagi S, et al. Influence of gender, age and renal function on plasma adiponectin level: the Tanno and Sobetsu study. Eur J Endocrinol 2005;153(1):91-8
15. Denzel MS, Scimia MC, Zumstein PM, et al. T-cadherin is critical for adiponectin-mediated cardioprotection in mice. J Clin Invest 2010;120(12):4342-52
16. Hug C, Wang J, Ahmad NS, et al. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci USA 2004;101(28):10308-13
17. Wei EK, Giovannucci E, Fuchs CS, et al. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst 2005;97(22):1688-94
18. Xu XT, Xu Q, Tong JL, et al. Metaanalysis: circulating adiponectin levels and risk of colorectal cancer and adenoma. J Dig Dis 2011;12(4):234-44
19. Joshi RK, Kim WJ, Lee SA. Association between obesity-related adipokines and colorectal cancer: a case-control study and meta-analysis. World J Gastroenterol 2014;20(24):7941-9
20. An W, Bai Y, Deng SX, et al. Adiponectin levels in patients with colorectal cancer and adenoma: a meta-analysis. Eur J Cancer Prev 2012;21(2):126-33
21. Nakajima TE, Yamada Y, Hamano T, et al. Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci 2010;101(5):1286-91
22. Byeon JS, Jeong JY, Kim MJ, et al. Adiponectin and adiponectin receptor in relation to colorectal cancer progression. Int J Cancer 2010;127(12):2758-67
23. Fujisawa T, Endo H, Tomimoto A, et al. Adiponectin suppresses colorectal carcinogenesis under the high-fat diet condition. Gut 2008;57(11):1531-8
24. Mantzoros C, Petridou E, Dessypris N, et al. Adiponectin and breast cancer risk. J Clin Endocrinol Metab 2004;89(3):1102-7
25. Oh SW, Park CY, Lee ES, et al. Adipokines, insulin resistance, metabolic syndrome, and breast cancer recurrence: a cohort study. Breast Cancer Res 2011;13(2):R34
26. Macis D, Gandini S, Guerrieri-Gonzaga A, et al. Prognostic effect of circulating adiponectin in a randomized 2 x 2 trial of low-dose tamoxifen and fenretinide in premenopausal women at risk for breast cancer. J Clin Oncol 2012;30(2):151-7
27. Miyoshi Y, Funahashi T, Kihara S, et al. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res 2003;9(15):5699-704
28. Dal Maso L, Augustin LS, Karalis A, et al. Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab 2004;89(3):1160-3
29. Benaitreau D, Dieudonn-e MN, Dos Santos E, et al. Antiproliferative effects of adiponectin on human trophoblastic cell lines JEG-3 and BeWo. Biol Reprod 2009;80(6):1107-14
30. Cong L, Gasser J, Zhao J, et al. Human adiponectin inhibits cell growth and induces apoptosis in human endometrial carcinoma cells, HEC-1-A and RL95. Endocr Relat Cancer 2007;14(3):713-20
31. Tsukada T, Fushida S, Harada S, et al. Adiponectin receptor-1 expression is associated with good prognosis in gastric cancer. J Exp Clin Cancer Res 2011;30:107
32. Shin E, Park do J, Kim HH, et al. Adiponectin receptor expression in gastric carcinoma: implications in tumor development and progression. J Cancer Res Clin Oncol 2013;139(4):709-18
33. Duggan C, Onstad L, Hardikar S, et al. Association between markers of obesity and progression from Barrett's esophagus to esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2013;11(8):934-43
34. Howard JM, Beddy P, Ennis D, et al. Associations between leptin and adiponectin receptor upregulation, visceral obesity and tumour stage in oesophageal and junctional adenocarcinoma. Br J Surg 2010;97(7):1020-7
35. Kotani K, Wakai K, Shibata A, et al. Serum adiponectin multimer complexes and liver cancer risk in a large cohort study in Japan. Asian Pac J Cancer Prev 2009;10(Suppl):87-90
36. Andreeva AV, Kutuzov MA. Cadherin 13 in cancer. Genes Chromosomes Cancer 2010;49(9):775-90
37. Kuhajda FP. AMP-activated protein kinase and human cancer: cancer metabolism revisited. Int J Obes (Lond) 2008;32(Suppl 4):S36-41
38. Meisse D, Van de Casteele M, Beauloye C, et al. Sustained activation of AMP-activated protein kinase induces c-Jun N-terminal kinase activation and apoptosis in liver cells. FEBS Lett 2002;526(1-3):38-42
39. Taliaferro-Smith L, Nagalingam A, Zhong D, et al. LKB1 is required for adiponectin-mediated modulation of AMPK-S6K axis and inhibition of migration and invasion of breast cancer cells. Oncogene 2009;28(29):2621-33
40. Adekola K, Rosen ST, Shanmugam M. Glucose transporters in cancer metabolism. Curr Opin Oncol 2012;24(6):650-4
41. Karim R, Tse G, Putti T, et al. The significance of the Wnt pathway in the pathology of human cancers. Pathology 2004;36(2):120-8
42. Wang Y, Lam JB, Lam KS, et al. Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res 2006;66(23):11462-70
43. Liu J, Lam JB, Chow KH, et al. Adiponectin stimulates Wnt inhibitory factor-1 expression through epigenetic regulations involving the transcription factor specificity protein 1. Carcinogenesis 2008;29(11):2195-202
44. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009;9(11):798-809
45. Miyazaki T, Bub JD, Uzuki M, Iwamoto Y. Adiponectin activates c-Jun NH2-terminal kinase and inhibits signal transducer and activator of transcription 3. Biochem Biophys Res Commun 2005;333(1):79-87
46. Zhang R, Wu J, Liu D, et al. Anti-inflammatory effect of full-length adiponectin and proinflammatory effect of globular adiponectin in esophageal adenocarcinoma cells. Oncol Res 2013;21(1):15-21
47. Kern PA, Saghizadeh M, Ong JM, et al. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995;95(5):2111-19
48. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 1994;43(11):1271-8
49. Nishimura S, Manabe I, Nagasaki M, et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med 2009;15(8):914-20
50. Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002;8(7):731-7
51. Tan PH, Tyrrell HE, Gao L, et al. Adiponectin receptor signaling on dendritic cells blunts anti-tumor immunity. Cancer Res 2014;74(20):5711-22
52. Folco EJ, Rocha VZ, López-Ilasaca M, Libby P. Adiponectin inhibits proinflammatory signaling in human macrophages independent of interleukin-10. J Biol Chem 2009;284(38):25569-75
53. Gove ME, Pini M, Fayad R, Cabay RJ. Adiponectin deficiency modulates adhesion molecules expression and cytokine production but does not affect disease severity in the transfer model of colitis. Cytokine 2009;47(2):119-25
54. Komura N, Maeda N, Mori T, et al. Adiponectin protein exists in aortic endothelial cells. PLoS One 2013;8(8):e71271
55. Kim KY, Kim JK, Han SH, et al. Adiponectin is a negative regulator of NK cell cytotoxicity. J Immunol 2006;176(10):5958-64
56. Park PH, McMullen MR, Huang H, et al. Short-term treatment of RAW264.7 macrophages with adiponectin increases tumor necrosis factor-alpha (TNF-alpha) expression via ERK1/2 activation and Egr-1 expression: role of TNF-alpha in adiponectinstimulated interleukin-10 production. J Biol Chem 2007;282(30):21695-703
57. Jung MY, Kim HS, Hong HJ, et al. Adiponectin induces dendritic cell activation via PLCgamma/JNK/NFkappaB pathways, leading to Th1 and Th17 polarization. J Immunol 2012;188(6):2592-601
58. Fan D, Li L, Wang C, et al. Adiponectin induces interleukin-6 production and its underlying mechanism in adult rat cardiac fibroblasts. J Cell Physiol 2011;226(7):1793-802
59. Kraus D, Winter J, Jepsen S, et al. Interactions of adiponectin and lipopolysaccharide from Porphyromonas gingivalis on human oral epithelial cells. PLoS ONE 2012;7(2):e30716
60. Tang CH, Chiu YC, Tan TW, et al. Adiponectin enhances IL-6 production in human synovial fibroblast via an AdipoR1 receptor, AMPK, p38, and NFkappa B pathway. J Immunol 2007;179(8):5483-92
61. Otero M, Lago R, Gomez R, et al. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65(9):1198-201
62. D'Anna R, Baviera G, Corrado F, et al. Adiponectin and insulin resistance in early-and late-onset pre-eclampsia. BJOG 2006;113(11):1264-9
63. Shoji T, Shinohara K, Hatsuda S, et al. Altered relationship between body fat and plasma adiponectin in end-stage renal disease. Metabolism 2005;54(3):330-4
64. Kumada M, Kihara S, Ouchi N, et al. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 2004;109(17):2046-9
65. Ohashi K, Parker JL, Ouchi N, et al. Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype. J Biol Chem 2010;285(9):6153-60
66. Wolf AM, Wolf D, Rumpold H, et al. Adiponectin induces the antiinflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun 2004;323(2):630-5
67. Kyriazi E, Tsiotra PC, Boutati E, et al. Effects of adiponectin in TNF-alpha, IL-6, and IL-10 cytokine production from coronary artery disease macrophages. Horm Metab Res 2011;43(8):537-44
68. Tsang JY, Li D, Ho D, et al. Novel immunomodulatory effects of adiponectin on dendritic cell functions. Int Immunopharmacol 2011;11(5):604-9
69. Park PH, Huang H, McMullen MR, et al. Activation of cyclic-AMP response element binding protein contributes to adiponectin-stimulated interleukin-10 expression in RAW 264.7 macrophages. J Leukoc Biol 2008;83(5):1258-66
70. Huang H, Park PH, McMullen MR, Nagy LE. Mechanisms for the antiinflammatory effects of adiponectin in macrophages. J Gastroenterol Hepatol 2008;23(Suppl 1):S50-3
71. Wulster-Radcliffe MC, Ajuwon KM, Wang J, et al. Adiponectin differentially regulates cytokines in porcine macrophages. Biochem Biophys Res Commun 2004;316(3):924-9
72. Mandal P, Pratt BT, Barnes M, et al. Molecular mechanism for adiponectindependent M2 macrophage polarization: link between the metabolic and innate immune activity of full-length adiponectin. J Biol Chem 2011;286(15):13460-9
73. Cheng X, Folco EJ, Shimizu K, Libby P. Adiponectin induces pro-inflammatory programs in human macrophages and CD4+ T cells. J Biol Chem 2012;287(44):36896-904
74. Katsuki A, Sumida Y, Urakawa H, et al. Plasma levels of adiponectin are associated with insulin resistance and serum levels of triglyceride in Japanese metabolically obese, normal-weight men with normal glucose tolerance. Diabetes Care 2003;26(10):2964-5
75. Tan PH, Sagoo P, Chan C, et al. Inhibition of NF-kappa B and oxidative pathways in human dendritic cells by antioxidative vitamins generates regulatory T cells. J Immunol 2005;174(12):7633-44
76. Kriketos AD, Gan SK, Poynten AM, et al. Exercise increases adiponectin levels and insulin sensitivity in humans. Diabetes Care 2004;27(2):629-30
77. Luo N, Wang X, Chung BH, et al. Effects of macrophage-specific adiponectin expression on lipid metabolism in vivo. Am J Physiol Endocrinol Metab 2011;301(1):E180-6
78. Takeda K, Kaisho T, Yoshida N, et al. Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. J Immunol 1998;161(9):4652-60
79. Niemand C, Nimmesgern A, Haan S, et al. Activation of STAT3 by IL-6 and IL-10 in primary human macrophages is differentially modulated by suppressor of cytokine signaling 3. J Immunol 2003;170(6):3263-72
80. Melillo JA, Song L, Bhagat G, et al. Dendritic cell (DC)-specific targeting reveals Stat3 as a negative regulator of DC function. J Immunol 2010;184(5):2638-45
81. Williams L, Bradley L, Smith A, Foxwell B. Signal transducer and activator of transcription 3 is the dominant mediator of the antiinflammatory effects of IL-10 in human macrophages. J Immunol 2004;172(1):567-76
82. Klotz L, Dani I, Edenhofer F, et al. Peroxisome proliferator-activated receptor gamma control of dendritic cell function contributes to development of CD4+ T cell anergy. J Immunol 2007;178(4):2122-31
83. Gosset P, Charbonnier AS, Delerive P, et al. Peroxisome proliferator-activated receptor gamma activators affect the maturation of human monocyte-derived dendritic cells. Eur J Immunol 2001;31(10):2857-65
84. Li Y, Chu N, Rostami A, Zhang GX. Dendritic cells transduced with SOCS-3 exhibit a tolerogenic/DC2 phenotype that directs type 2 Th cell differentiation in vitro and in vivo. J Immunol 2006;177(3):1679-88
85. Shibata R, Sato K, Pimentel DR, et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK-and COX-2-dependent mechanisms. Nat Med 2005;11(10):1096-103
86. Chinetti G, Zawadski C, Fruchart JC, Staels B. Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARalpha, PPARgamma, and LXR. Biochem Biophys Res Commun 2004;314(1):151-8
87. Wilk S, Scheibenbogen C, Bauer S. Adiponectin is a negative regulator of antigen-activated T cells. Eur J Immunol 2011;41(8):2323-32
88. Tsuchida A, Yamauchi T, Ito Y. Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem 2004;279(29):30817-22
89. Palanivel R, Fang X, Park M, et al. Globular and full-length forms of adiponectin mediate specific changes in glucose and fatty acid uptake and metabolism in cardiomyocytes. Cardiovasc Res 2007;75(1):148-57
90. Tomizawa A, Hattori Y, Kasai K, Nakano Y. Adiponectin induces NFkappaB activation that leads to suppression of cytokine-induced NFkappaB activation in vascular endothelial cells: globular adiponectin vs. high molecular weight adiponectin. Diab Vasc Dis Res 2008;5(2):123-7
91. Okamoto Y, Folco EJ, Minami M, et al. Adiponectin inhibits the production of CXC receptor 3 chemokine ligands in macrophages and reduces T-lymphocyte recruitment in atherogenesis. Circ Res 2008;102(2):218-25
92. Okamoto Y, Christen T, Shimizu K, et al. Adiponectin inhibits allograft rejection in murine cardiac transplantation. Transplantation 2009;88(7):879-83
93. Sun Y, Zang Z, Zhong L, et al. Identification of adiponectin receptor agonist utilizing a fluorescence polarization based high throughput assay. PLoS ONE 2013;8(5):e63354
94. Otvos L Jr, Haspinger E, La Russa F, et al. Design and development of a peptide-based adiponectin receptor agonist for cancer treatment. BMC Biotechnol 2011;11:90
95. Okada-Iwabu M, Yamauchi T, Iwabu M, et al. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature 2013;503(7477):493-9
96. Higgins LS, Depaoli AM. Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation. Am J Clin Nutr 2010;91(1):267S-72S
97. Pishvaian MJ, Marshall JL, Wagner AJ, et al. A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies. Cancer 2012;118(21):5403-13
98. Maeda N, Takahashi M, Funahashi T, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001;50(9):2094-9
99. Smallridge RC, Copland JA, Brose MS, et al. Efatutazone, an oral PPAR-g agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial. J Clin Endocrinol Metab 2013;98(6):2392-400
100. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011;29:235-71
101. Koebel CM, Vermi W, Swann JB, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007;450(7171):903-7
102. De Rosa V, Procaccini C, Cal G, et al. A key role of leptin in the control of regulatory T cell proliferation. Immunity 2007;26(2):241-55
103. Ferroni P, Palmirotta R, Spila A, et al. Prognostic significance of adiponectin levels in non-metastatic colorectal cancer. Anticancer Res 2007;27(1B):483-9
104. Erarslan E, Turkay C, Koktener A, et al. Association of visceral fat accumulation and adiponectin levels with colorectal neoplasia. Dig Dis Sci 2009;54(4):862-8
105. Kemik O, Sumer A, Kemik AS, et al. The relationship among acute-phase response proteins, cytokines and hormones in cachectic patients with colon cancer. World J Surg Oncol 2010;8:85
106. Gialamas SP, Petridou ET, Tseleni-Balafouta S, et al. Serum adiponectin levels and tissue expression of adiponectin receptors are associated with risk, stage, and grade of colorectal cancer. Metabolism 2011;60(11):1530-8
107. Song M, Zhang X, Wu K, et al. Plasma adiponectin and soluble leptin receptor and risk of colorectal cancer: a prospective study. Cancer Prev Res (Phila) 2013;6(9):875-85
108. Aleksandrova K, Boeing H, Jenab M, et al. Total and high-molecular weight adiponectin and risk of colorectal cancer: the European Prospective Investigation into Cancer and Nutrition Study. Carcinogenesis 2012;33(6):1211-18
109. Lukanova A, Soderberg S, Kaaks R, et al. Serum adiponectin is not associated with risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2006;15(2):401-2
110. Stocks T, Lukanova A, Johansson M, et al. Components of the metabolic syndrome and colorectal cancer risk; a prospective study. Int J Obes (Lond) 2008;32(2):304-14
111. Shahar S, Salleh RM, Ghazali AR, et al. Roles of adiposity, lifetime physical activity and serum adiponectin in occurrence of breast cancer among Malaysian women in Klang Valley. Asian Pac J Cancer Prev 2010;11(1):61-6
112. Korner A, Pazaitou-Panayiotou K, Kelesidis T, et al. Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies. J Clin Endocrinol Metab 2007;92(3):1041-8
113. Chen DC, Chung YF, Yeh YT, et al. Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett 2006;237(1):109-14
114. Duggan C, Irwin ML, Xiao L, et al. Associations of insulin resistance and adiponectin with mortality in women with breast cancer. J Clin Oncol 2011;29(1):32-9
115. Kang JH, Yu BY, Youn DS. Relationship of serum adiponectin and resistin levels with breast cancer risk. J Korean Med Sci 2007;22(1):117-21
116. Hou WK, Xu YX, Yu T, et al. Adipocytokines and breast cancer risk. Chin Med J (Engl) 2007;120(18):1592-6
117. Tworoger SS, Eliassen AH, Kelesidis T, et al. Plasma adiponectin concentrations and risk of incident breast cancer. J Clin Endocrinol Metab 2007;92(4):1510-16
118. Gaudet MM, Falk RT, Gierach GL, et al. Do adipokines underlie the association between known risk factors and breast cancer among a cohort of United States women Cancer Epidemiol 2010;34(5):580-6
119. Cust AE, Kaaks R, Friedenreich C, et al. Plasma adiponectin levels and endometrial cancer risk in pre-and postmenopausal women. J Clin Endocrinol Metab 2007;92(1):255-63
120. Ma Y, Liu Z, Zhang Y, Lu B. Serum leptin, adiponectin and endometrial cancer risk in Chinese women. J Gynecol Oncol 2013;24(4):336-41
121. Bohlouli S, Khazaei M, Teshfam M, et al. Adiponectin effect on the viability of human endometrial stromal cells and mRNA expression of adiponectin receptors. Int J Fertil Steril 2013;7(1):43-8
122. Nakajima TE, Yamada Y, Hamano T, et al. Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer. J Gastroenterol 2009;44(7):685-90
123. Ishikawa M, Kitayama J, Kazama S, et al. Plasma adiponectin and gastric cancer. Clin Cancer Res 2005;11(2 Pt 1):466-72
124. Seker M, Bilici A, Sonmez B, et al. The association of serum adiponectin levels with histopathological variables in gastric cancer patients. Med Oncol 2010;27(4):1319-23
125. Yildirim A, Bilici M, Ç ayr K, et al. Serum adiponectin levels in patients with esophageal cancer. Jpn J Clin Oncol 2009;39(2):92-6
126. Nakajima TE, Yamada Y, Hamano T, et al. Adipocytokines and squamous cell carcinoma of the esophagus. J Cancer Res Clin Oncol 2010;136(2):261-6
127. Diao Y, Li H, Li H, et al. Association of serum levels of lipid and its novel constituents with the different stages of esophageal carcinoma. Lipids Health Dis 2009;8:48
128. Grote VA, Rohrmann S, Dossus L, et al. The association of circulating adiponectin levels with pancreatic cancer risk: a study within the prospective EPIC cohort. Int J Cancer 2012;130(10):2428-37
129. Stolzenberg-Solomon RZ, Weinstein S, Pollak M, et al. Prediagnostic adiponectin concentrations and pancreatic cancer risk in male smokers. Am J Epidemiol 2008;168(9):1047-55
130. Bao Y, Giovannucci EL, Kraft P, et al. A prospective study of plasma adiponectin and pancreatic cancer risk in five US cohorts. J Natl Cancer Inst 2013;105(2):95-103
131. Chang MC, Chang YT, Su TC, et al. Adiponectin as a potential differential marker to distinguish pancreatic cancer and chronic pancreatitis. Pancreas 2007;35(1):16-21
132. Krechler T, Zeman M, Vecka M, et al. Leptin and adiponectin in pancreatic cancer: connection with diabetes mellitus. Neoplasma 2011;58(1):58-64
133. Dalamaga M, Migdalis I, Fargnoli JL, et al. Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: a case-control study. Cancer Causes Control 2009;20(5):625-33
134. Sumie S, Kawaguchi T, Kuromatsu R, et al. Total and high molecular weight adiponectin and hepatocellular carcinoma with HCV infection. PLoS One 2011;6(11):e26840
135. Spyridopoulos TN, Petridou ET, Skalkidou A, et al. Low adiponectin levels are associated with renal cell carcinoma: a case-control study. Int J Cancer 2007;120(7):1573-8
136. Pinthus JH, Kleinmann N, Tisdale B, et al. Lower plasma adiponectin levels are associated with larger tumor size and metastasis in clear-cell carcinoma of the kidney. Eur Urol 2008;54(4):866-73
137. Horiguchi A, Ito K, Sumitomo M, et al. Decreased serum adiponectin levels in patients with metastatic renal cell carcinoma. Jpn J Clin Oncol 2008;38(2):106-11
138. Liao LM, Schwartz K, Pollak M, et al. Serum leptin and adiponectin levels and risk of renal cell carcinoma. Obesity (Silver Spring) 2013;21(7):1478-85
139. Li H, Stampfer MJ, Mucci L, et al. A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin Chem 2010;56(1):34-43
140. Burton A, Martin RM, Holly J, et al. Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: the ProtecT study. Cancer Causes Control 2013;24(2):323-34
141. Michalakis K, Williams CJ, Mitsiades N, et al. Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study. Cancer Epidemiol Biomarkers Prev 2007;16(2):308-13
142. Arisan ED, Arisan S, Atis G, et al. Serum adipocytokine levels in prostate cancer patients. Urol Int 2009;82(2):203-8
143. Goktas S, Yilmaz MI, Caglar K, et al. Prostate cancer and adiponectin. Urology 2005;65(6):1168-72
144. Baillargeon J, Platz EA, Rose DP, et al. Obesity, adipokines, and prostate cancer in a prospective population-based study. Cancer Epidemiol Biomarkers Prev 2006;15(7):1331-5
145. Kerenidi T, Lada M, Tsaroucha A, et al. Clinical significance of serum adipokines levels in lung cancer. Med Oncol 2013;30(2):507
146. Petridou ET, Mitsiades N, Gialamas S, et al. Circulating adiponectin levels and expression of adiponectin receptors in relation to lung cancer: two case-control studies. Oncology 2007;73(3-4):261-9
147. Karapanagiotou EM, Tsochatzis EA, Dilana KD, et al. The significance of leptin, adiponectin, and resistin serum levels in non-small cell lung cancer (NSCLC). Lung Cancer 2008;61(3):391-7
148. Petridou ET, Sergentanis TN, Antonopoulos CN, et al. Insulin resistance: an independent risk factor for lung cancer Metabolism 2011;60(8):1100-6
149. Qi GM, Jia LX, Li YL, et al. Adiponectin suppresses angiotensin II-induced inflammation and cardiac fibrosis through activation of macrophage autophagy. Endocrinology 2014;155(6):2254-65
150. Yamauchi T, Kamon J, Waki H, et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 2003;278(4):2461-8
151. Zhang C, Liao Y, Li Q, et al. Recombinant adiponectin ameliorates liver ischemia reperfusion injury via activating the AMPK/eNOS pathway. PLoS ONE 2013;8(6):e66382
152. Summer R, Little FF, Ouchi N, et al. Alveolar macrophage activation and an emphysema-like phenotype in adiponectin-deficient mice. Am J Physiol Lung Cell Mol Physiol 2008;294(6):L1035-42
153. Okamoto Y, Ishii S, Croce K, et al. Adiponectin inhibits macrophage tissue factor, a key trigger of thrombosis in disrupted atherosclerotic plaques. Atherosclerosis 2013;226(2):373-7
154. Yokota T, Oritani K, Takahashi I, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000;96(5):1723-32
155. Awazawa M, Ueki K, Inabe K, et al. Adiponectin enhances insulin sensitivity by increasing hepatic IRS-2 expression via a macrophage-derived IL-6-dependent pathway. Cell Metab 2011;13(4):401-12
156. Wang Y, Wang X, Lau WB, et al. Adiponectin inhibits tumor necrosis factor-alpha-induced vascular inflammatory response via caveolinmediated ceramidase recruitment and activation. Circ Res 2014;114(5):792-805
157. van Meurs M, Castro P, Shapiro NI, et al. Adiponectin diminishes organspecific microvascular endothelial cell activation associated with sepsis. Shock 2012;37(4):392-8
158. Yu F, Chen R, Takahashi T, et al. Candesartan improves myocardial damage in obese mice with viral myocarditis and induces cardiac adiponectin. Int J Cardiol 2008;129(3):414-21
159. Kobashi C, Urakaze M, Kishida M, et al. Adiponectin inhibits endothelial synthesis of interleukin-8. Circ Res 2005;97(12):1245-52
160. Shibata R, Skurk C, Ouchi N, et al. Adiponectin promotes endothelial progenitor cell number and function. FEBS Lett 2008;582(11):1607-12
161. Yokota T, Meka CS, Kouro T, et al. Adiponectin, a fat cell product, influences the earliest lymphocyte precursors in bone marrow cultures by activation of the cyclooxygenaseprostaglandin pathway in stromal cells. J Immunol 2003;171(10):5091-9
162. Wanninger J, Neumeier M, Weigert J, et al. Adiponectin-stimulated CXCL8 release in primary human hepatocytes is regulated by ERK1/ERK2, p38 MAPK, NF-kappaB, and STAT3 signaling pathways. Am J Physiol Gastrointest Liver Physiol 2009;297(3):G611-18
163. Thakur V, Pritchard MT, McMullen MR, Nagy LE. Adiponectin normalizes LPS-stimulated TNF-alpha production by rat Kupffer cells after chronic ethanol feeding. Am J Physiol Gastrointest Liver Physiol 2006;290(5):G998-1007
164. Shibata R, Ouchi N, Ito M, et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 2004;10(12):1384-9
165. Masaie H, Oritani K, Yokota T, et al. Adiponectin binds to chemokines via the globular head and modulates interactions between chemokines and heparan sulfates. Exp Hematol 2007;35(6):947-56